Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.
There are few surprises but some interesting insights into company strategies in the House Oversight and Reform Committee staff’s investigative reports on pricing and marketing practices for Bristol Myers Squibb Company/Celgene Corporation’s cancer drug Revlimid (lenalidomide) and Teva’s Copaxone (glatiramer) for multiple sclerosis.
The reports aim to build a case for drug pricing legislation (HR 3) that passed the House last year and...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
